See more : Commerce Resources Corp. (CMRZF) Income Statement Analysis – Financial Results
Complete financial analysis of Galecto, Inc. (GLTO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Galecto, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Hubei Fuxing Science and Technology Co.,Ltd (000926.SZ) Income Statement Analysis – Financial Results
- NICE Ltd. (NICE.TA) Income Statement Analysis – Financial Results
- The ONE Enterprise Public Company Limited (ONEE.BK) Income Statement Analysis – Financial Results
- Hosokawa Micron Corporation (6277.T) Income Statement Analysis – Financial Results
- Prime Energy P.E. Ltd (PRIM.TA) Income Statement Analysis – Financial Results
Galecto, Inc. (GLTO)
About Galecto, Inc.
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is based in Boston, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 830.00K | 490.00K | 441.00K | 188.00K | 111.00K | 0.00 |
| Gross Profit | -830.00K | -490.00K | -441.00K | -188.00K | -111.00K | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 23.77M | 48.21M | 38.49M | 24.63M | 36.53M | 10.09M |
| General & Administrative | 12.69M | 13.00M | 13.74M | 9.01M | 2.45M | 2.81M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 12.69M | 13.00M | 13.74M | 9.01M | 2.45M | 2.81M |
| Other Expenses | 3.45M | 0.00 | 0.00 | 0.00 | 1.91M | -479.00K |
| Operating Expenses | 35.63M | 61.21M | 52.23M | 33.64M | 38.97M | 12.91M |
| Cost & Expenses | 36.46M | 61.21M | 52.23M | 33.64M | 38.97M | 12.91M |
| Interest Income | 1.69M | 722.00K | 156.00K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 417.00K | 0.00 | 0.00 | 0.00 | 2.97M |
| Depreciation & Amortization | 830.00K | 490.00K | 441.00K | 188.00K | 111.00K | 12.91K |
| EBITDA | -37.52M | -61.13M | -51.31M | -34.65M | -36.40M | -12.90M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -39.91M | -61.21M | -52.23M | -33.64M | -38.97M | -12.91M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 1.56M | -417.00K | 475.00K | -1.20M | 2.46M | -2.96M |
| Income Before Tax | -38.35M | -61.62M | -51.75M | -34.84M | -36.51M | -15.87M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 417.00K | -475.00K | 1.20M | 1.91M | 2.48M |
| Net Income | -38.35M | -62.04M | -51.28M | -36.04M | -38.42M | -15.87M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -36.08 | -61.04 | -50.75 | -35.66 | -37.76 | -4.42 |
| EPS Diluted | -36.08 | -61.04 | -50.75 | -35.66 | -37.76 | -4.42 |
| Weighted Avg Shares Out | 1.06M | 1.02M | 1.01M | 1.01M | 1.02M | 1.02M |
| Weighted Avg Shares Out (Dil) | 1.06M | 1.02M | 1.01M | 1.01M | 1.02M | 1.02M |
Galecto Announces First Patient Treated in Phase 2 Trial of Oral Galectin-3 Inhibitor GB1211 in Liver Cirrhosis
Galecto now has three ongoing Phase 2 clinical trials with three different drug candidates in three high value indications Galecto now has three ongoing Phase 2 clinical trials with three different drug candidates in three high value indications
Galecto Announces First Patient Treated in Phase 2a Trial of the Oral LOXL2 Inhibitor GB2064 in Myelofibrosis (the MYLOX-1 Trial)
BOSTON, Aug. 18, 2021 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced the treatment of the first patient in a Phase 2a trial of its...
Galecto Reports Second Quarter Operating and Financial Results
BOSTON, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced its operating and financial results for the quarter ended June 30,...
Galecto's GB0139 Shows Favorable Safety and Tolerability Profile with Promising Changes in Efficacy Markers in Hospitalized COVID-19 Patients
BOSTON and COPENHAGEN, Denmark, June 22, 2021 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a publicly listed, clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced preliminary topline results from an investigator-initiated...
GLTO Stock Price: 60% Increase Explanation
The stock price of Galecto Inc (NASDAQ: GLTO) increased by 60% today. This is why it happened.
Galecto Reports First Quarter Financial Results and Provides a Corporate Update
BOSTON, May 04, 2021 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced its operating and financial results for the period ended March 31,...
Galecto (GLTO) Enters Oversold Territory
Galecto (GLTO) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock
Galecto Reports Financial Results for the Year Ended December 31, 2020 and Provides a Corporate Update
BOSTON, March 29, 2021 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced its operating and financial results for the year ended December 31,...
UPDATE: Galecto Hosting Expert Perspective Panel on the Evolving Treatment Landscape for Idiopathic Pulmonary Fibrosis and Potential for GB0139
Tuesday, March 30, 2021 @ 2pm Eastern Time Tuesday, March 30, 2021 @ 2pm Eastern Time
Galecto Hosting Expert Perspective Panel on the Evolving Treatment Landscape for Idiopathic Pulmonary Fibrosis and Potential for GB0139
Tuesday, March 30, 2021 @ 2pm Eastern Time. Tuesday, March 30, 2021 @ 2pm Eastern Time.
Source: https://incomestatements.info
Category: Stock Reports